Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q2

9987.TEDINET S100PLBR
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.14T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.10T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥14.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥7.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥16.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥16.5bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥13.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.19Tat 2022-09-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.16Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥764.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥429.1bnat 2022-09-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥422.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥132.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥155.8bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.2bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥159.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥28.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥37.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥17.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥11.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥123.362022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.862022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥103.752021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.922021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio35.9%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥107.1bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥19.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥87.2bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥930m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥644m
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.07T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥25.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥22.7bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥17.2bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.27T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.14T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥129.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥14.7bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥85.3bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥19.4bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥65.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥13m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.06T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.03T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥25.8bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥21.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥15.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.21T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥107.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥7.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Work in processCurrentQuarterInstant1874000000JPY
Raw materials and suppliesPrior1YearInstant4938000000JPY
Raw materials and suppliesCurrentQuarterInstant4887000000JPY
Other caPrior1YearInstant26006000000JPY
Other caCurrentQuarterInstant27217000000JPY
Allowance for doubtful accounts caPrior1YearInstant-930000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-1438000000JPY
Current assetsPrior1YearInstant882936000000JPY
Current assetsCurrentQuarterInstant923822000000JPY
Property plant and equipmentPrior1YearInstant119116000000JPY
Property plant and equipmentCurrentQuarterInstant124902000000JPY
GoodwillPrior1YearInstant1180000000JPY
GoodwillCurrentQuarterInstant1082000000JPY
Other iaPrior1YearInstant9996000000JPY
Other iaCurrentQuarterInstant9712000000JPY
Intangible assetsPrior1YearInstant11177000000JPY
Intangible assetsCurrentQuarterInstant10794000000JPY
Investment securitiesPrior1YearInstant89969000000JPY
Investment securitiesCurrentQuarterInstant94751000000JPY
Other ioaPrior1YearInstant38928000000JPY
Other ioaCurrentQuarterInstant39473000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-410000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-318000000JPY
Investments and other assetsPrior1YearInstant128487000000JPY
Investments and other assetsCurrentQuarterInstant133906000000JPY
Noncurrent assetsPrior1YearInstant258780000000JPY
Noncurrent assetsCurrentQuarterInstant269603000000JPY
AssetsPrior1YearInstant1141717000000JPY
AssetsCurrentQuarterInstant1193426000000JPY
Notes and accounts payable tradePrior1YearInstant664280000000JPY
Notes and accounts payable tradeCurrentQuarterInstant689619000000JPY
Income taxes payablePrior1YearInstant6355000000JPY
Income taxes payableCurrentQuarterInstant5428000000JPY
Provision for bonusesPrior1YearInstant6646000000JPY
Provision for bonusesCurrentQuarterInstant7067000000JPY
Provision for loss on anti monopoly act clPrior1YearInstant5475000000JPY
Provision for loss on anti monopoly act clCurrentQuarterInstant5475000000JPY
Other clPrior1YearInstant15120000000JPY
Other clCurrentQuarterInstant30196000000JPY
Current liabilitiesPrior1YearInstant697879000000JPY
Current liabilitiesCurrentQuarterInstant737788000000JPY
Provision for directors retirement benefitsPrior1YearInstant26000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant－JPY
Net defined benefit liabilityPrior1YearInstant2310000000JPY
Net defined benefit liabilityCurrentQuarterInstant2331000000JPY
Other nclPrior1YearInstant23439000000JPY
Other nclCurrentQuarterInstant24249000000JPY
Noncurrent liabilitiesPrior1YearInstant25776000000JPY
Noncurrent liabilitiesCurrentQuarterInstant26580000000JPY
LiabilitiesPrior1YearInstant723655000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass